FD inhibitors should also be evaluated in clinical trials either as add-on therapy for C3 glomerulopathy patients, or for aHUS patients in whom C5 inhibition is insufficient, or as an alternative therapy. The gene discussed is C5; the disease is atypical hemolytic-uremic syndrome.